Clinical trials: Tislelizumab
Pancreatic Cancer
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
The purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-PD-1 antibody) in combination with SX-682 (a CXCR1/2 inhibitor) in subjects with newly diagnosed and surgically resectable…
- Trial name
- NCT05604560
- Testing
- Tislelizumab, SX-682
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Lei Zheng
Ovarian Cancer, mRNA Vaccine
A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery
This is a Phase I, single-arm, open-label, prospective, non-randomized, single-center dose-escalation study. The study will evaluate the safety, tolerability, and preliminary activity of the NeoOVSV mRNA-lipid nanoparticle…
- Trial name
- NeoOVSV (NCT07724106)
- Testing
- Low Dose, middle dose, high dose
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Advanced Solid Tumors
A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.
The purpose of this study is to evaluate the safety and primary efficacy of the combination therapy of recombinant human IL-21-expressing oncolytic vaccinia virus (hV01) and the PD-1 Inhibitor Tislelizumab in patients with…
- Trial name
- NCT07185243
- Testing
- recombinant human IL-21-expressing oncolytic vaccinia virus injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hangzhou Converd Co., Ltd.
Intrahepatic Cholangiocarcinoma
TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma
This study is a prospective, multicenter, open, real-world clinical study. All eligible patients were assigned to experimental group (TACE combined with multi-target drugs and PD-1 inhibitors), and control group (conventional…
- Trial name
- NCT05247996
- Testing
- Transcatheter arterial chemoembolization, Multi-target Drug Therapy, Immunocheckpoint Inhibitor Therapy
- Volunteers
- 98 people
- Sponsor
- The Central Hospital of Lishui City
Locally Advanced and Metastatic Solid Tumors
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
The primary objectives of this study were: to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217…
- Trial name
- NCT04047862
- Testing
- Ociperlimab, Tislelizumab, Pemetrexed
- Where
- 65 sites in United States, Australia and 4 more
- Volunteers
- 446 people
- Sponsor
- BeiGene
Colorectal Neoplasms
Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.
Long course radiotherapy plus neoadjuvant chemotherapy followed by resection total mesorecta excision has accepted widespread recognized in the treatment of locally advanced rectal cancer (LARC).
- Trial name
- NCT04911517
- Testing
- long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing Friendship Hospital
Esophageal Squamous Cell Carcinoma
PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer
The goal of this observational study is to learn about in potential operable esophageal cancer patients (cT1-2N + M0 and cT3NanyM0) receiving neoadjuvant therapy.
- Trial name
- PPIO-004-EC001 (NCT05880082)
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Biliary Tract Cancer, PD-1 Antibody
Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
The aim of this study is to assess the R0 resection rate of tislelizumab combined with Lenvatinib and Gemox chemotherapy in the conversion therapy of potentially resectable locally advanced BTC.
- Conditions
- Biliary Tract Cancer, PD-1 Antibody, Gemox, Lenvatinib
- Trial name
- NCT05156788
- Testing
- PD-1+Lenvatinib+GEMOX
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Uveal Melanoma With Liver Metastases
Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
SITISVEAL stablish the hypothesis that treatment with Tislelizumab + Sitravatinib will increase the Objective Response Rate in patients with Metastatic Uveal Melanoma with liver metastases, compared with the current standard of…
- Trial name
- SITISVEAL (NCT05542342)
- Testing
- Tislelizumab, Sitravatinib
- Where
- 4 sites in Spain
- Volunteers
- 16 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Recurrent Pancreatic Cancer
Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer
To evaluate the efficacy of Tislelizumab combined with Nab-paclitaxel and Gemcitabine in the treatment of recurrent pancreatic cancer
- Trial name
- NCT04902261
- Testing
- Tislelizumab, Nab paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Changhai Hospital
HCC - Hepatocellular Carcinoma
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
Postoperative recurrence remains a major limitation to long-term survival in hepatocellular carcinoma (HCC). In addition, a narrow surgical margin is widely regarded as a risk factor for recurrence.
- Trial name
- NCT07518706
- Testing
- Tislelizumab, Lenvatinib
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
Ablation Combined With PD-1 in HCC: Phase II Study
This is a Phase 2, single arm, single center study designed to evaluate the safety and tolerability of radiofrequency or microwave ablation combined with PD-1 monoclonal antibody in patients with hepatocellular carcinoma(HCC)…
- Trial name
- NCT04652440
- Testing
- PD-1 monoclonal antibody, Radiofequencey or microwave ablation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Muscle Invasive Bladder Cancer, Urothelial Carcinoma
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma
This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as perioperative treatment in patients with muscle-invasive bladder cancer (MIBC) prior to cystectomy or…
- Trial name
- NCT04730219
- Testing
- Tislelizumab, Nab paclitaxel
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Tianjin Medical University Second Hospital
Hodgkin Lymphoma (Category)
BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma
The goal of this clinical trial is to explore the real-world Chinese relapsed/refractory patients to evaluate the efficacy and safety of BV monotherapy or combination therapy in CHL patients.
- Trial name
- NCT06761911
- Testing
- Brentuximab Vedotin (Bv), Sintilimab, Tislelizumab
- Volunteers
- 100 people
- Sponsor
- Xiuhua Sun
Resectable Esophageal Squamous Cell Carcinoma
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the pathological complete response (pCR) in participants receiving tislelizumab plus chemotherapy/chemoradiotherapy as neoadjuvant treatment.
- Trial name
- RATIONALE-213 (NCT04974047)
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 8 sites in China
- Volunteers
- 70 people
- Sponsor
- BeiGene
Immunotherapy
Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer
To compare the efficacy of Neoadjuvant Chemoradiotherapy Combined With/without Tislelizumab in the Treatment of Locally Advanced Rectal Cancer
- Trial name
- NCT05479240
- Testing
- Tislelizumab, Capecitabine, oxaliplatin
- Volunteers
- 94 people
- Sponsor
- Fujian Cancer Hospital
Intrahepatic Cholangiocarcinoma
HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma
Primary liver cancer is the sixth most common cancer worldwide, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, of which intrahepatic cholangiocarcinoma accounts for 10%-15%.
- Trial name
- NCT05290116
- Testing
- HAIC Combined with Tislelizumab and Apatinib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Yunfei Yuan
Metastatic Castration-resistant Prostate Cancer (CRPC)
Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.
- Trial name
- NCT06249750
- Testing
- Immunotherapy, Targeted therapy, Hyperthermia
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Pengyuan Liu
Hepatocellular Carcinoma
Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
Study on the therapeutic effect of different infusion times on tislelizumab in high-risk postoperative hepatocellular carcinoma
- Trial name
- NCT07243691
- Testing
- Tislelizumab: 200mg, intravenous infusion, Q3W
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sir Run Run Shaw Hospital
Triple Negative Breast Cancer
Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study
Triple-negative breast cancer (TNBC) lacks effective treatment options due to the absence of traditional therapeutic targets.This study is a multicentre, prospective trial.
- Trial name
- TEMPLATE (NCT04913571)
- Testing
- Eribulin, Tislelizumab
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Fudan University